BioSante Pharmaceuticals, Inc. NASDAQ:BPAX Strong
Seite 44 von 47 Neuester Beitrag: 27.02.12 20:06 | ||||
| Eröffnet am: | 27.12.10 18:13 | von: Trader-3007 | Anzahl Beiträge: | 2.162 |
| Neuester Beitrag: | 27.02.12 20:06 | von: Mr-Bean | Leser gesamt: | 97.871 |
| Forum: | Hot-Stocks | Leser heute: | 44 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 41 | 42 | 43 | | 45 | 46 | 47 > | ||||
Und negative Meinung nicht tolleriert sondern Sie direkt als Basher bezeichnet werde ich mal ein paar Posting der negativen Art hier reinstellen.
Warum sollte BPAX diese Zulassung denn in andere Kursregionen führen Leute?
Sie haben eine MK von jetzt 120 Millionen Dollar.
Sie bekommen jetzt EINMALIG 10 Millionen Dollar und dann 5% vom Verkauf des Produkts von TEVA.
LEUTE DAS IST DOCH NICHTS WAS EINE HÖHERE MK RECHTFERTIGT.
Ihr habt heute morgen noch Kurse von 2 Dollar usw. für heute in den Mund genommen.
Und was ist jetzt?
Es werden so viele Shares gehandelt und es wird nicht gecovert denn das würde den Kurs steigen lassen.
Oder ich vermute es wird gecovert und gleichzeitig laden da GROSSE stark ab die froh sind die Aktie nochmal so gut gut loszuwerden.
Denkt dran so wie Ihr andere hier im Forum behandelt so werdet Ihr selber behandelt.
Mich als Basher hinzustellen ist das letzte.
Dies ist genauso wahrscheinlich wie eure höheren Kursanpreisungen.
Aber paßt bloß auf das TEVA heute nicht noch besser performt als BPAX hier.
Zielkurs könnte heute 0,89 Dollar sein dort liegt ein dicker fetter Brocken.Ob der noch bedient wird?
Das ASK ist komplett zu und zwar auf fast jedem Dollarcent.
Da wollen noch einige aussteigen warum nur!!!!
***dann rutscht es unter 1 Dollar*** ne das ist kein bashen
komm lüg in deine eigene tasche kopfschüttel ;-(
servu$
Jipi
Ach so Falke ich bin short geganngen zu 1,14 Dollar heute ist doch klar.
Jetzt gleich unter 1 Dollar das rutscht und bringt gutes Geld in meine Tasche.
Wer ist denn immer noch in diesem SCAM drin???
Kauft lieber TEVA.
Meiner Meinung nach besteht bei BPAX eher die Chance auf ein Chappter11 in den nächsten 24 Monaten als auf Kurse über 3 Dollar.
Ist ja nur meine Meinung mehr nicht.
Ist sonst noch jemand short gegangen heute??
2012-02-15 08:20 ET - News Release
NEW YORK, NY -- (MARKET WIRE) -- 02/15/12
Biotech stocks have been on an impressive run in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. The iShares Nasdaq Biotechnology Index Fund -- which contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals -- is up more than 16 percent this year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:
www.paragonreport.com/BPAX
www.paragonreport.com/CTIC
Earlier this month The Food and Drug Administration's (FDA) much anticipated guidelines for the sale of lower-cost versions of biotechnology drugs required studies showing that the generic copies are "highly similar" to the originals, but there are several ways that might be proven. According to market analysis firm Datamonitor, the worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Shares of the company were hammered in late January after the company voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy. Shares of Cell Therapeutics are lagging the industry this year and are down more than 7 percent in 2012.
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. Its lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction. Earlier this month the company announced in a statement that the independent Data Monitoring Committee has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. Shares of BPAX are up more than 50 percent year-to-date.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
Zeitpunkt: 16.02.12 11:57
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Mehrfachposting. Spam.
Du bezeichnest mich ja schon wieder als Basher warum?
Zähl mal deine positiven Postings heute und setze meine negativen dagenen.
Also wenn ich mit den wenigen Postings ein BASHER bin was bist Du denn dann ein OBEROBER-PUSHER oder was??
Pack Dir mal an deine eigene Nase ich äußere nur meine Meinung aber Du beleidigst hier.
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: ANI Pharmaceuticals |
smilie_tra_065.gif
und der mod von sharedeals schreibt um 18:13 Feb "biosante offizielle news link"
mehr als 1h später hehe man sind die aktuell ;-)
servu$
2012-02-15 12:00 ET - News Release
Mr. Stephen Simes reports
BIOSANTE PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR BIO-T-GEL LINCOLNSHIRE, ILLINOIS(FEBRUARY 15, 2012)
BioSante Pharmaceuticals, Inc.'s Bio-T-Gel, which is licensed by BioSante to Teva Pharmaceuticals USA Inc. has been approved by the United States Food and Drug Administration (FDA). Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels. Male hypogonadism is generally characterized by impotence, a lack of sex drive, muscle weakness and osteoporosis.
Bio-T-Gel was initially developed by BioSante, and then it was licensed to Teva for late stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive royalties and may receive certain milestone payments upon commercialization of Bio-T-Gel. The current U.S. market for male testosterone products is estimated at over $1.6 billion.
"We are pleased that Bio-T-Gel will provide another treatment option to men suffering from low testosterone levels," said Stephen M. Simes, BioSante's president & CEO. "We are confident that Teva has the commercialization and marketing expertise to implement a successful launch, and we look forward to Bio-T-Gel reaching the market."
About Male Hypogonadism
Typically, a man's testosterone level is considered low if it's below a level of approximately 300 ng/dL. Low testosterone affects 4 to 5 million men over the age of 39 and is associated with a multitude of symptoms including loss of libido and sexual function, decreased energy, increased body fat, osteoporosis, reduced muscle mass, and loss of body hair. There is no cure for hypogonadism. It is a medical condition that usually require